Case Studies

Sientra markets and distributes silicone breast implants and other aesthetic implants into the $600m US market. The company broke the breast implant market duopoly in March of 2012 when it received approval from the FDA for its silicone implant. Silicone implants were being sold by Mentor (J&J) and Inamed (Allergan) after the FDA re-introduced them into the US market in 2006. Sientra was founded in 2006 when highly respected aesthetics industry veteran, Hani Zeini, went in search of ‘the next big thing’ in aesthetics. Hani bought the Sientra products from a team that had already begun a clinical trial and Sientra submitted a PMA in 2008. 

Post-approval investment

We were extremely impressed with the management team but mitigated FDA risk by investing upon approval in 2012, leading the $65m series C financing and taking a board seat. Since then the company has hired a full sales team, developed a business with sales revenue tracking over $50m, and has began working toward profitability. In October 2014 Sientra went public on Nasdaq raising $80m.

BACK
Business
Aesthetic Implants
Indication
Focus on breast implants
Stage
Products launched in the US
Initial Investment
March 2012
Listing
New York
Outcome
IPO on Nasdaq

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News
  3. Film

Contact

  1. Contact Us
  2. Send Us Your Proposal
Case Study

Sientra markets and distributes silicone breast implants and other aesthetic implants into the $600m US market. The company broke the breast implant market duopoly in March of 2012 when it received approval from the FDA for its silicone implant. Silicone implants were being sold by Mentor (J&J) and Inamed (Allergan) after the FDA re-introduced them into the US market in 2006. Sientra was founded in 2006 when highly respected aesthetics industry veteran, Hani Zeini, went in search of ‘the next big thing’ in aesthetics. Hani bought the Sientra products from a team that had already begun a clinical trial and Sientra submitted a PMA in 2008. 

Post-approval investment

We were extremely impressed with the management team but mitigated FDA risk by investing upon approval in 2012, leading the $65m series C financing and taking a board seat. Since then the company has hired a full sales team, developed a business with sales revenue tracking over $50m, and has began working toward profitability. In October 2014 Sientra went public on Nasdaq raising $80m.

Business
Aesthetic Implants
Indication
Focus on breast implants
Stage
Products launched in the US
Initial Investment
March 2012
Listing
New York
Outcome
IPO on Nasdaq
BACK
 
Copyright Abingworth 2017